New and developing non-adrenoreceptor small molecule drugs for the treatment of asthma

Thomson, N. C. (2017) New and developing non-adrenoreceptor small molecule drugs for the treatment of asthma. Expert Opinion on Pharmacotherapy, 18(3), pp. 283-293. (doi: 10.1080/14656566.2017.1284794) (PMID:28099820)

136080.pdf - Accepted Version



Introduction: Inhaled corticosteroids (ICS) alone or in combination with an inhaled long-acting beta2-agonist (LABA) are the preferred long-term treatment for adults and adolescents with symptomatic asthma. Additional drugs include leukotriene-receptor antagonists, slow-release theophylline and the long-acting muscarinic antagonist (LAMA) tiotropium (approved in 2015). There is a need for more effective therapies, as many patients continue to have poorly controlled asthma. Areas covered: New and developing long-acting non-adrenoreceptor synthetic drugs for the treatment of symptomatic chronic asthma despite treatment with an ICS alone or combined with a LABA. Data was reviewed from studies published up until November 2016. Expert opinion: Tiotropium improves lung function and has a modest effect in reducing exacerbations when added to ICS alone or ICS and LABA. The LAMAs umeclidinium and glycopyrronium are under development in fixed dose combination with ICS and LABA. Novel small molecule drugs, such as CRTH2 receptor antagonists, PDE4 inhibitors, protein kinase inhibitors and nonsteroidal glucocorticoid receptor agonists and ‘off-label’ use of licensed drugs, such as macrolides and statins are under investigation for asthma, although their effectiveness in clinical practice is not established. To better achieve the goal of developing effective novel small molecule drugs for asthma will require greater understanding of mechanisms of disease and the different phenotypes and endotypes of asthma.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Thomson, Professor Neil
Authors: Thomson, N. C.
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Journal Name:Expert Opinion on Pharmacotherapy
Publisher:Taylor & Francis
ISSN (Online):1744-7666
Published Online:01 February 2017
Copyright Holders:Copyright © 2017 Informa UK Limited, trading as Taylor and Francis Group
First Published:First published in Expert Opinion on Pharmacotherapy 18(3): 283-293
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record